Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.

31 Although GLP-1RAs have consistently reduced CV and all-cause mortality in patients with chronic kidney disease, or T2D and established atherosclerotic CVD and/or high CV disease, 4 the present analysis in those with HFpEF showed only a nonsignificant trend toward lower mortality in CV or all-cause mortality.

also in 5,406 other papers